BioSpace News Archive

Aucta Pharmaceuticals, Inc. announced the commercial launch of MOTPOLY XR extended-release capsules C-V. MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

XYRA LLC is pleased to announce today it has reached agreement with the FDA (“Agency”) at a series of End of Phase 2 (EoP2) meetings, on the key studies that will form the basis of approval and labeling of orally administered budiodarone for the long-term management of symptomatic non-permanent atrial fibrillation (AF).

TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor.

Rallybio Corporation today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Orphan Bone & Neuromuscular Diseases,” at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 9:10 a.m. EST.

UroGen Pharma Ltd. today announced that it will present at TD Cowen’s 44th Annual Health Care Conference on Monday, March 4, 2024 at 1:30pm EST.

Baseimmune , a biotech company that uses proprietary, deep learning AI to predict future pathogen mutations to generate novel vaccines, announced the close of $11.3 million [£9 million] in Series A funding led by new investor.

Alpha Tau Medical Ltd. today announced that management will participate at the Barclays 26th Annual Global Healthcare Conference on March 12th and 13th, 2024.

Inozyme Pharma, Inc. today announced Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscular Diseases panel presentation at the TD Cowen 44th Annual Health Care Conference.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings.

Fusion Pharmaceuticals Inc. today announced that the Company will participate in two upcoming investor conferences.